TY - JOUR
T1 - Interference with the Jaffé method for creatinine following 5-aminolevulinic acid administration
AU - Quon, Harry
AU - Grossman, Craig E.
AU - King, Rebecca L.
AU - Putt, Mary
AU - Donaldson, Keri
AU - Kricka, Larry
AU - Finlay, Jarod
AU - Zhu, Timothy
AU - Dimofte, Andrea
AU - Malloy, Kelly
AU - Cengel, Keith A.
AU - Busch, Theresa M.
N1 - Funding Information:
This study was supported in part by the National Institutes of Health (R01-CA-129554), American Cancer Society (IRG-78-002-28) and T32-CA-009677 (CG). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
PY - 2010/12
Y1 - 2010/12
N2 - Background: The photosensitizer pro-drug 5-aminolevulinic acid (5-ALA) has been administered systemically for photodynamic therapy. Although several toxicities have been reported, nephrotoxicity has never been observed. Materials and methods: Patients with head and neck mucosal dysplasia have been treated on a phase 1 study of escalating light doses in combination with 60. mg/kg of oral 5-ALA. Serum creatinine was measured with the modified Jaffe method or an enzymatic method in the first 24. h after 5-ALA. Interference by 5-ALA, as well as by its photosensitizing product protoporphyrin IX, was assessed. Results: Among 11 subjects enrolled to date, 9 of 11 had blood chemistries collected within the first 5. h with 7 demonstrating significant grade 3 creatinine elevations (p=0.030). There was no additional evidence of compromised renal function or increased PDT-induced mucositis. Creatinine levels measured by the Jaffe assay increased linearly as a function of the ex vivo addition of ALA (p< 0.0001). The exogenous addition of PpIX did not alter creatinine levels. ALA did not interfere with creatinine levels as measured by an enzymatic assay. A total of 4 of the 11 subjects had creatinine levels prospectively measured by both the Jaffe and the enzymatic assays. Only the Jaffe method demonstrated significant elevations as a function of time after ALA administration. Conclusions: The transient increase in creatinine after systematic ALA can be attributed, in part, if not entirely, to interference of ALA in the Jaffe reaction. Alternative assays should be employed in situations calling for monitoring of kidney function after systemic ALA.
AB - Background: The photosensitizer pro-drug 5-aminolevulinic acid (5-ALA) has been administered systemically for photodynamic therapy. Although several toxicities have been reported, nephrotoxicity has never been observed. Materials and methods: Patients with head and neck mucosal dysplasia have been treated on a phase 1 study of escalating light doses in combination with 60. mg/kg of oral 5-ALA. Serum creatinine was measured with the modified Jaffe method or an enzymatic method in the first 24. h after 5-ALA. Interference by 5-ALA, as well as by its photosensitizing product protoporphyrin IX, was assessed. Results: Among 11 subjects enrolled to date, 9 of 11 had blood chemistries collected within the first 5. h with 7 demonstrating significant grade 3 creatinine elevations (p=0.030). There was no additional evidence of compromised renal function or increased PDT-induced mucositis. Creatinine levels measured by the Jaffe assay increased linearly as a function of the ex vivo addition of ALA (p< 0.0001). The exogenous addition of PpIX did not alter creatinine levels. ALA did not interfere with creatinine levels as measured by an enzymatic assay. A total of 4 of the 11 subjects had creatinine levels prospectively measured by both the Jaffe and the enzymatic assays. Only the Jaffe method demonstrated significant elevations as a function of time after ALA administration. Conclusions: The transient increase in creatinine after systematic ALA can be attributed, in part, if not entirely, to interference of ALA in the Jaffe reaction. Alternative assays should be employed in situations calling for monitoring of kidney function after systemic ALA.
UR - http://www.scopus.com/inward/record.url?scp=78649635428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649635428&partnerID=8YFLogxK
U2 - 10.1016/j.pdpdt.2010.07.008
DO - 10.1016/j.pdpdt.2010.07.008
M3 - Article
C2 - 21112550
AN - SCOPUS:78649635428
SN - 1572-1000
VL - 7
SP - 268
EP - 274
JO - Photodiagnosis and Photodynamic Therapy
JF - Photodiagnosis and Photodynamic Therapy
IS - 4
ER -